Podcasts about seqster

In this interview, Ardy Arianpour, CEO and co-founder of SEQSTER, shares his journey from growing up in San Diego, immersed in life sciences, to becoming a leader in the healthcare tech space. He discusses his passion for innovation, the power of family support, and how his personal experiences with Alzheimer's shaped his mission to revolutionize healthcare with data and AI. Ardy's story highlights the importance of caring, authenticity, and mission-driven leadership in creating meaningful change. 00:53- About Ardy Arianpour Ardy Arianpour is the CEO and co-founder of SEQSTER. He is a global HealthTech leader and speaker.

In a new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with Dr Brigham Hyde, co-founder and CEO of Atropos Health, and Ardy Arianpour, co-founder and CEO of SEQSTER, about their latest partnership, with its goal of personalised registries and the notion of the digital front door for patient information.

This Wednesday's #TheShot of #digitalhealth therapy was infused by the energy of ⬥ Ardy Arianpour ⬥, CEO and Founder of SEQSTER. Jim Joyce and I had a blast talking all things:

When Seqster was first founded in 2016, co-founder Ardy Arianpour had a lot of experience in next-gen sequencing and a vision for how consumers could control their health information. Arianpour envisioned a place where anyone can bring all their health data together in one place and share it on their terms. Since then, Arianpour says he has found many parts of the business challenging. There have been shifts in the business model over time, which began as direct-to-consumer. He credits Seqster's 2020 agreement with Takeda Pharmaceuticals as a tipping point. Now, with several pharma partnerships to boast, Seqster is more than a company, Arianpour insists to host, Deborah Borfitz, in the latest Scope of Things podcast. “This is a movement.” Links from this episode:  Seqster's Perfect Timing, Powerful Platform Might Change Health Clinical Research News Seqster 

Hosts Gil Bashe and Gregg Masters welcome Ardy Arianpour CEO & Co-Founder of SEQSTER the leading healthcare technology company that puts the patient at the center of all their health data. He is a visionary health tech executive with 20+ years driving innovation in biotech, life sciences and digital health. Prior to starting SEQSTER, Ardy launched several clinical and consumer-based genetic tests as Chief Commercial Officer of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of What That Means, Camille gets into digital health and personalized medicine with Ardy Arianpour, CEO and Co-Founder at SEQSTER. They talk about the fragmentation of digital health between health systems, the questions of privacy and security in personalized medicine, and the coming possibilities for leveraging health data. The views and opinions expressed are those of the guests and author and do not necessarily reflect the official policy or position of Intel Corporation.

This is the fifth and last episode of the Healthcare Data in the US series. In the first one, Arif Nathoo - CEO and co-founder of Komodo Health, described how the company is planning to capture and de-identify every encounter patients have with the US healthcare system. The second episode featured Phil Lindemann, VP of Business Intelligence at Epic, and Epic's Clinical Informaticist Dave Little, who talked about Epic Cosmos - a database of EHR data from 178 million patients. In the third episode, Samir Unni, Business Development Lead for Healthcare at Palantir Foundry, explained the principles of Palantir in healthcare, why they support an open-data approach, how knowledge from other industries is transferred to healthcare and more.  In the fourth episode, representatives of four companies working on automating care tasks, providing clinicians with clinical decision support, and creating synthetic data records, four industry experts shared their experience with building solutions on top of EHRs, challenges related to connecting to electronic health records, and the need for better interoperability APIs to really enable data to be used for health outcomes improvement. In this final episode,  Ardy Arianpour, CEO of Seqster, explains for Seqster provides its clients with an operating system for researching of clinical and tracking patient data to create new solutions. Enjoy the discussion and tune into other episodes as well. This series will be summarized in our newsletter - find it and subscribe at fodh.substack.com www.facesofdigitalhealth.com Seqster: https://www.seqster.com/

Ardy Arianpour is CEO & Co-Founder of Seqster the leading healthcare technology company that puts the patient at the center of all their health data. He is a visionary health tech executive with 20+ years driving innovation in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He was a Medical, Marketing, and Media's (MM&M) Top 40 Healthcare Transformer and San Diego Business Journal 40 under 40. In this episode we discuss health data silos, the history of Seqster, digital front door use cases, and which Metallica album is best.

Ardy Arianpour, CEO and Co-Founder of SEQSTER, is breaking down health data silos using their enterprise operating system, which aggregates disparate health data sources, including real-world data, into a single 360-degree view of a patient in real-time. This integrated approach with a Digital Front Door solves many challenges for life sciences, patient engagement, and data interoperability. Ardy elaborates, "We have achieved nationwide coverage of electronic health records from hospitals and medical groups, as well as genomic DNA labs, wearables, remote patient monitoring sensors, pharmacy data, and even social determinants of health data. And we have this very unique customizable white label approach where SEQSTER provides accelerated access to de-identified tokenized real-time data and comprehensive curated data to address critical needs across the healthcare continuum." "For about five years, nobody wanted to work with us. We were just building, building, building, being visionary, as we thought. Then the pandemic hit, and Takeda Pharmaceuticals decided to invest in SEQSTER and do a commercial deal with us. From there, we created the SEQSTER data backbone for Takeda to centralize all this health data. And since we pioneered a longitudinal health record and pharma was the first to take a look at our technology, from there, we are able to strike many partnerships. We just exploded in the last two and a half years, I could say." @SEQSTER #PatientCentric #HealthDataIsMedicine #PatientEngagement #ClinicalTrials #DecentralizedTrials #Interoperability #OutcomesStudies #HEOR #RWD #RWE #SaaS. #SanDiego SEQSTER.com Medium Article: Participant Digital Front Door Download the transcript here

Ardy Arianpour, CEO and Co-Founder of SEQSTER, is breaking down health data silos using their enterprise operating system, which aggregates disparate health data sources, including real-world data, into a single 360-degree view of a patient in real-time. This integrated approach with a Digital Front Door solves many challenges for life sciences, patient engagement, and data interoperability. Ardy elaborates, "We have achieved nationwide coverage of electronic health records from hospitals and medical groups, as well as genomic DNA labs, wearables, remote patient monitoring sensors, pharmacy data, and even social determinants of health data. And we have this very unique customizable white label approach where SEQSTER provides accelerated access to de-identified tokenized real-time data and comprehensive curated data to address critical needs across the healthcare continuum." "For about five years, nobody wanted to work with us. We were just building, building, building, being visionary, as we thought. Then the pandemic hit, and Takeda Pharmaceuticals decided to invest in SEQSTER and do a commercial deal with us. From there, we created the SEQSTER data backbone for Takeda to centralize all this health data. And since we pioneered a longitudinal health record and pharma was the first to take a look at our technology, from there, we are able to strike many partnerships. We just exploded in the last two and a half years, I could say." @SEQSTER #PatientCentric #HealthDataIsMedicine #PatientEngagement #ClinicalTrials #DecentralizedTrials #Interoperability #OutcomesStudies #HEOR #RWD #RWE #SaaS. #SanDiego SEQSTER.com Medium Article: Participant Digital Front Door Listen to the podcast here

Precision medicine harnesses the power of genetic data, which can improve treatment regimens and overall outcomes for patients. But accessing that data remains another challenge. Field correspondent Kate Pecora speaks with advocate Christine Von Raesfeld about how patient access to data can be a game-changer, and what can be done to expand that across the chronic disease community. Plus, did you see your 2022 Medicare premium go up? Terry and Dr. Bob discuss why. They also deliver health policy updates from Capitol Hill that impact patients, including new legislation introduced that would shed light on the practices of drug supply chain middlemen known as pharmacy benefit managers (PBMs). And June marks National Scleroderma Awareness Month. Patient correspondent Amy shares why more research funding is needed to understand this illness.Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public InterestKate Pecora, Field CorrespondentGuests: Christine Von Raesfeld, CEO and Founder, People with EmpathyAmy Gietzen, Patient Correspondent Links: E&C Leaders Unveil FDA User Fees Legislative Package | Democrats, Energy and Commerce Committee2022 Medicare CostsStatement from HHS Secretary Becerra: 2022 Medicare Part B Premium Increase Attributable to Alzheimer's Drug AduhelmMDUFA Up for Renewal, Congress Recommends a Facelift | Patients Rising Now  June Is National Scleroderma Awareness Month | NIAMSPharmacy Benefit Manager Transparency Act of 2022Grassley, Cantwell Introduce Bipartisan Bill to Combat Rising Prescription Drug Prices and Provide More TransparencyPatients Rising Now Submits Comments to the FTC on the Impact of Pharmacy Benefit Managers on PatientsPatients Rising Now Joins over 100 Associations on Pharmacy Benefit Managers LetterProsperdtx Launches Strategic Collaboration with Health Equity Researchers and Seqster to Improve Health Equity for Cancer PatientsNeed help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

In a world where companies like Meta, Google, and Apple collect and benefit from vast amounts of data about you, what would it be like if you were in control of your data instead? Specifically, what would it be like if you were in control of your health data? And what if you had it all in one easy to access place?CEO and Co-Founder Ardy Arianpour came on the podcast to tell Dave Anderson how and why Seqster is giving people that kind of control over their own health data. Adry says patient-centric data interoperability is healthcare's biggest challenge and it's his number one mission.Seqster is a technology company working to break down the silos within the world of healthcare and make health data interoperability easy and universal.Making Health Data InteroperableData is the gold of the twenty-first century. But interoperability of data is the moonshot. It's not enough to collect the data, it also needs to be accessible and usable, and it turns out interoperability is hard to do. Ardy says that Seqster is the first company to make the idea work.Dave asks why interoperability is so hard to do. It's because lab data is different from wearable data, which is different from data from your doctor, which is different from data from your dentist, and so on. All your data needs to be extracted and keyed in such a way it can be cross referenced.But putting it all together isn't enough. You must also think about the patient's experience. “How do you connect the dots quickly and how do you visualize this data?"The data needs to be easy for both patients and providers to access and read. "What are they going to do with my data?”You're already giving your doctor and other providers access to your data. But you're not really in control of it from that point on. This year, the U.S. Centers for Medicare & Medicaid Services interoperability rules stated that every single patient must have access to their healthcare data. Seqster wants to put the patient in control.Dave follows up by asking what is being done with all this data? Who is using it and how?It's mostly clinical and decentralized trials, Ardy says. By using these data sets, both the cost and the time required to complete trials and develop new pharmaceuticals and therapies are vastly reduced.  Imagine what happens when you can collect a million patients' data in an hour versus 18 months and then look at them all in one place? Ardy says we get more accurate information which results in better and faster development of new medicines and vaccines. Breaking down the silos that contain health data allows for a bigger picture of health for all of us.With enough data, from enough patients, and with the right funding, Ardy thinks cancer is a problem we can solve. Dave wonders if health data could be like being an organ donor. Could we mark a box on a form and agree to donate our health data to science after our deaths?Listen to this episode to learn more about: The problems around siloed health data and his solutionHow to address privacy concerns around healthcare dataArdy's personal journey that brought him to this fieldWhy Big Pharma isn't evilBill Gates's advice to Ardy on getting Seqster to scaleThe decade of biological revolutionThe business model to make this work

Ardy Arianpour, CEO and founder of Seqster, shares his thoughts on why DNA is the ultimate tool for healthcare interoperability, what opportunities exist at the intersection of digital health and life science, and why a strong mission trumps a traditional business plan.

Your medical records don't make pleasant bedtime reading. And not only are they inscrutable—they're often mutually (and deliberately) incompatible, meaning different hospitals and doctor's offices can't share them across institutional boundaries. Harry's guest this week, Ardy Arianpour, is trying to fix all that. He's the co-founder and CEO of Seqster, a San Diego company that's spent the last five years working on ways to pull patient data from all the places where it lives, smooth out all the formatting differences, and create a unified picture that patients themselves can understand and use.The way Ardy explains it, Seqster “smashes the data siloes.” Meaning, the company can combine EMR data, gene sequence data, wearable device data, pharmacy data, and insurance claims data all in one place. The big goal guiding Seqster, he says, is to put the patient back at the center of healthcare.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.Full TranscriptHarry Glorikian: Hello. I'm Harry Glorikian. Welcome to The Harry Glorikian Show, the interview podcast that explores how technology is changing everything we know about healthcare. Artificial intelligence. Big data. Predictive analytics. In fields like these, breakthroughs are happening way faster than most people realize. If you want to be proactive about your own health and the health of your loved ones, you'll need to learn everything you can about how medicine is changing and how you can take advantage of all the new options.Explaining this approaching world is the mission of my new book, The Future You. And it's also our theme here on the show, where we bring you conversations with the innovators, caregivers, and patient advocates who are transforming the healthcare system and working to push it in positive directions.If you've ever gotten a copy of your medical files from your doctor or hospital, you probably know these records don't make pleasant bedtime reading. They aren't designed to be clear or user-friendly for patients. In fact, it's usually just the opposite.The data itself is highly technical. And on top of that, there's the inscrutable formatting, which is dictated by whatever electronic medical record or “EMR” system your provider happens to use. But the problem isn't just that EMR data is incomprehensible.It's also that different EMRs are often incompatible with each other.So if you're being treated by multiple providers, it can be really tricky to share your data across institutional boundaries. That's why medicine is one of the last industries that still uses old-fashioned fax machines. Because sometimes a fax is the only way to send the data back and forth.But my guest today is trying to fix all that.His name is Ardy Arianpour, and he's the co-founder and CEO of Seqster.It's a company in San Diego that's spent the last five years working on ways to pull patient data from all the places where it lives, smooth out all the formatting differences, and create a unified picture that patients themselves can understand and use.The way Ardy explains it, Seqster quote-unquote “smashes the data siloes.” Meaning, the company can combine EMR data, gene sequence data, wearable device data, pharmacy data, and insurance claims data all in one place.The big goal guiding Seqster, according to Ardy, is to put the patient back at the center of healthcare.At the moment, however, consumers can't sign up for the service directly. Seqster's actual customers are players from inside the healthcare industry. For example, a life science companies might hire Seqster to help them make the experience of participating in a clinical trial more user friendly for patients.Or a health plan might use a Seqster dashboard to get patients more involved in their own care.Seqster did let me do a test run on my own medical data as part of my research for this interview. And I was impressed by how quickly it pulled in data that normally lives in a bunch of separate places. I'm hoping Seqster and other companies in this space will continue to make progress.Because, frankly, I think poor patient access to health data and the lack of interoperability between EMRs are two of the biggest factors holding back improvements in healthcare quality.If we can finally get those two things right, I think it can help unlock the data-driven healthcare revolution that I describe in my new book, The Future You. Which, by the way, is out now in paperback and ebook format at Barnes & Noble and Amazon.When we spoke back in September, Ardy and I talked about better EMRs and many other things. And now here's our conversation.Harry Glorikian: Ardy, welcome to the show. So, it's good to have you here, and you know, for everybody who doesn't know your story and the story of the company, I'd love to, you know, start covering some basics like, you know, the when, the what, the how, the why. What's the founding story of Seqster and what was the problems that you were really trying to go out there and solve when you started the company in 2016?Ardy Arianpour: Thanks so much, Harry. Always been a fan. I think we've known each other for quite some time, but it's been a long time since we've ran into each other since the genomic and precision medicine days. So great to see you. I hope you and your family are well and yeah, look, Seqster is super special and there's a secret story, I guess, that never has been told. It really starts way beyond 2016 when I founded the company. So I spent 15 plus years in DNA sequencing, next gen sequencing genomic market. And during that time in the 2000s to early 2010s, I was fortunate enough of being part of some amazing endeavors and organizations that allowed my team and I to take some risk. And when you take risk, when you're in biotech, pharma, precision medicine, genomics, bioinformatics, you learn new things that most people don't learn because you're you're you're, you know, trailblazing, I guess you could say. And we were able to do that back with one of my old companies where we were able to launch the first clinical exome test, launch the first BRCA cancer panels, launch the first next gen sequencing panels in a CLIA lab. Ardy Arianpour: And then, you know, it wasn't about the testing. It was all about the data, and we didn't realize that till later and we kept on seeing that wow genome data is really only one set of all the other data pieces, right? I think the genomics folks, me being a genomics guy, I guess you could say, for a decade and a half, we're so forward thinking that we forget about the simple things within science, and we never really thought, Oh, collect your medical data and pair it with your genomic data. We never really thought there would be a wearable out there. That data was going to be siloed, too. We never thought there was going to be, you know, many different medical devices and instruments that would be Bluetooth and sensor enabled, where there would be data that would be siloed. Claims data, pharmacy data. Never even crossed our minds. So, you know, when you put this all together, my inspiration with Seqster was actually really simple. And when I founded the company, I wanted to combine the genomic data with your EMR medical data as well as your wearable data, because in 2016, the tailwinds of those other, you know, services was really taken off.Harry Glorikian: Right. Totally understand it. And you know, as we were talking about before I hit record, it's like it was funny because I was just talking to another company that's working on NLP and they're able to look at, you know, papers and see drugs being used in different, you know, medical conditions. And then they figured out, well, they needed to tap into the unstructured data of a medical record to really, like, add the next layer of value to it. So, you know, there's a lot of activity going on about there. But how do you guys, how do you, how do your co-founders, you know, Zhang and Dana play into like the science, the technology and what's the sort of angle that you guys have taken to solve this problem? Or what's your idea on how to fix it? I'm not saying it's been solved yet, because that would be a Herculean task in and of itself. But how are you guys approaching it that? Is a little different than the. You know, maybe any any of your other you would you would consider anybody else out there, the working on this?Ardy Arianpour: Yeah, look for us we spent a lot of time understanding the power of data. But how what makes Seqster different is no one knows the power of the patient better than us. We've spent time with our platform with, you know, tens of thousands of patients: rare disease patients, oncology patients, parents, autoimmune disease patients, patients that have that are seeing functional medicine folks. Patients that were having issues sharing data through telemedicine, clinical trial patients. All these sorts of patients are very different. At Seqster we focused on putting the patient at the center of health care in order to smash all the data silos from their medical institutions to their wearable technology that they wear to the DNA testing that they get and even maybe a COVID test or a vaccine. How do you bring a 360-degree patient view? And you know, you tried the system, so I think you got a small teaser of how we can do that and we've really cracked this large problem. It is Herculean, I believe, and a lot of people believe because it's interoperability, it is the number one problem in all of health care.Harry Glorikian: Yeah, I mean, I had the pleasure of trying it and imported my data and was able to see, you know, individual pieces. I mean, I made some suggestions on what might make it easier for me to hone in in different areas, right, and have the system highlighting different things. But I guess each data stream is being brought in separately and then at some point you're going to create a master dashboard above it, because now each one is separate from when I go into each record, right, When I go into my medical record, it gives me one set of data with my lab results and everything else and the notes, and then it pulls in my wearable data separately that I have to look at, right? So you've got to look at it separately. It doesn't. Then I guess the next step would be creating a master sort of view of how everything would look in a sort of I don't want to say integrated, but at least a timeline view of the world. But. You know, following up on the the sort of the what question, you know, how do you sort of combine data from different EMRs, tests, apps, devices in a sort of scalable, repeatable way? I mean, it seems like to date, that's been a hugely manual process, and I can imagine you could figure out every provider's ontology and then create a table that shows what's equivalent to. And but you know, there's got to be sort of a translation scheme that would be required that that provides some constant readjustment as the main providers tweak and evolve their own systems, right? Because if the provider is tweaking their system, your system has then got to adapt to changes that are happening in that end. So how are you guys managing all that craziness?Ardy Arianpour: Yeah. So I think it all and you hit on so many points, I'll try and cover them if I remember them all. Look, the number one thing for us is we can connect to any data source. It doesn't matter. And you saw it. And just before I continue, just tell the audience how fast, how fast, how long did it take for your data to be populated after you connected it?Harry Glorikian: Oh, it was. I mean, yeah, as soon as I created it, I could see that it was, you know, it was digesting and then populating. And, you know, I was just I was watching it as a matter of fact, when I was on the phone with your person, that was helping me. Yeah. At first I said, Oh, it's not there. And then a couple of seconds later, I'm like, Oh no, it's showing up, right? So it was happening in, I don't want to say real time, but it was happening as as we were watching it evolve, right? It was sort of it was. It was almost like watching time lapse.Ardy Arianpour: And that's actually a great way. That's a great way to actually describe it. We created the time lapse of all your health data. Now let's get to the what and the how. So we connect to any health data source. The patient is fully in control. You own your data, you control it. It's all consented by you. We don't own your data and we connect to every single medical record. And that's huge that we've achieved nationwide coverage. We didn't know what data you have, but we're you're able to connect to it. Why? Because our team, which our engineering team gets all the credit for six years now, almost since founding of the company we have written, I don't know, seven million lines of code, that standardizes and harmonizes all of the ICD 9, ICD 10, SNOMED codes and every single lab result to every single wearable terminology, from biking to cycling to, you know, you name it, VitaminDB, you know, characterized in 40 different ways. You know, we're harnessing data to improve patient lives at scale. We built it for scale because you can't do it by the traditional method of just faxes and PDFs. Now, you know, being able to do that is not a bad thing.Ardy Arianpour: We can bring that service into our platform as well. It's already integrated, but that type of service takes 30 to 60 days and it's static data. It's not real time right now. If Harry goes, I don't know, you go on a bike ride and you fall and you go to the E.R. and you had whatever data connected automatically in your sister portal, it'll be populated without you even touching Seqster. That's how our real time data works and another way that we're totally differentiated than anything else in the marketplace. I was never a fan of API businesses because they're just data in data out. I truly wanted us to create a patient engagement platform, a PEP right, or a patient relationship management system, what I call a PRM instead of a CRM. And that's what we created with Seqster. So that is beyond an API, beyond just data. We're visualizing the data, as you saw. We really nailed the longitudinal health record or the individualized health record. And I think it's, I always say this, health data is medicine. The reason why it's medicine is because our platform has saved patient lives.Harry Glorikian: Ardy, how do you, how are you handling the free form notes, right, because I noticed that I could look at all my notes, but they weren't necessarily, it wasn't pulling from the note and sort of making sense of it. I mean, I could look at all of it and it was all in one place. But the the system wasn't necessarily processing it, sort of. I was talking to Jeff Felton from ConcertAI and they do a lot of sort of, their big thing is the NLP that sort of tries to choose chew through that, which is not trivial, you know, yesterday today, context matters in health care.Ardy Arianpour: Yeah. Look, if we created the the the Tesla of health care, let's just say, right, we're we're changing the game. From static data to real time data. Ok. Well, you're talking about is, are you going to create a helicopter as well? Right, OK. And all right. So, no, we're not going to go create the helicopter. Is there going to be an electric helicopter by Tesla? There's no market for that, right? So that's why they're not doing it now. I'm not saying there's not a market for NLP. It's just the fact that we'll go ahead and partner with a third party NLP provider. And we already have we have like four of them and they all have their strengths and weaknesses because it's not a one size fits all thing. And you know, we can already run OCR, you know, over the free text and pull certain ontology information out. And then, you know, when you partner with an NLP company, once you have a system that can capture data, you could do anything. So people always ask me, Are you going to get into AI? It's just the buzzword. There's a million A.I. companies. What have they really done right in health care? It's not really there. Maybe for imaging they've done some things, but it's more of a buzzword. AI only becomes valuable if you have a system, Harry, that can instantly populate data, then you can run some great artificial intelligence things on it. So NLP, AI, OCR, all those things are just many tools that can add. Now, in your experience, you only got to see about 5 percent of the power of Seqster, and that probably blew you away, even though it was five percent of the power. Because you probably never -- I don't know, you tell me, have you ever been able to collect your data that quickly? It took, what, less than a minute or two?Harry Glorikian: Yeah, well, thank God, I don't have a lot of data. So, you know, just when I tap into my my health care provider, you know, my data is there and it's funny, I always tell people, being a not exciting patient is a really good thing in one way, and it's a really bad thing because you can't play with all the data. But you know, like even when I did my genome, it's an extremely boring genome.Ardy Arianpour: My question is it's not about it being exciting or not, because thankfully you're not a chronically ill patients. But imagine if you were and how this helps, but take a step back. I'm just asking the speed, yes, and the quality of the presentation of the data that seeks to you. It was less than what hundred seconds?Harry Glorikian: Yeah. Well, it was very quick. And I've already it's funny because I texted my doctor and I was like, I need to talk to you about a couple of these lab results that look out of out of norm, right? And they weren't anything crazy. But I'm just curious like, you know, how do I get them in norm? I'm just I'm always trying to be in in the normal band, if I can be.Ardy Arianpour: So it's interesting you say that because as a healthy individual. You know, and even a chronically ill patient, it doesn't matter. The best way to actually QC data is through visualization, and this is what this is. That's foundational to interoperability. So we hit on semantic and structural interoperability with our, you know, backend engine that we've created to harmonize and standardize the data. We built many different types of retrievers and then we parse that data and then it's standardized and harmonizes it. But that visualization, which some people call the Tableau of health data, you know that we've created when they see it, is really, we got to give the credit to the patients. We had so many patients, healthy ones and unhealthy ones that told us exactly how they want it to look. We did this on the genomic data, we did this on the wearable data. We did this on the medical device data and we have some great new features that can superimpose your clinical data with your fitness data on our integrated view and timeline.Harry Glorikian: Oh, that? See, now that would be, you know, another level of value, even for a healthy patient, right to be able to see that in an integrated way. I made a suggestion, I think that when a panel shows up is. You know, highlight the ones that are out of Norm very quickly, as opposed to having to look at, you know, the panel of 20 to find the one that's out of whack, just either color them differently or reorient them so that they're easier to find. But those are simple changes just from a UI perspective. But so. How would you describe that that Seqster creates value and say translates that into revenue, right? I'm just trying to figure out like, what's the revenue model for you guys? I know that you're I can actually, I'm not even sure if I can sign up for it myself. I would probably have to do it through a system if I remember your revenue model correctly. But how do you guys generate revenue from what you're doing?Ardy Arianpour: Yeah, I'll share another secret on your show here from the founding of Seqster. My dream was to empower seven billion people on our little mothership here called Earth to have all their health data in one place. And I had a direct to consumer model in 2016. The market wasn't really ready for it, number one. Number two, it was going to cost $500 million worth of marketing to just get the message out for people to know that it exists. So long story short, in 2016, you know, when I founded the company, not that many people wanted to talk to us. They thought we were just like nuts to go after this problem. 2017, we got some calls from some investors, we raised some great seed funding after I personally put in some money in in 2016 to get the company going. And then in 2018, I got a call from Bill Gates and that was when everything changed. Bill called and wanted to meet in person, I was supposed to get 30 minutes with him. And the reason why he called is because our first beachhead was with Alzheimer's patients. My grandmother, both my grandmothers, passed away due to Alzheimer's disease. Both my maternal and paternal grandmothers and being a caregiver for my mom's mom and being very close to her since she raised me, I learned a lot about a multigenerational health record, so I actually filed patents in 2016 on a multigenerational health record because I wanted to have my grandma's data, my mom's data, my data, and be able to pass it on to research as well as to generations down my family.Ardy Arianpour: Long story short there, Bill gets all the credit for telling me after I showed him our platform, "You got to take this enterprise. You guys built something that Google Health failed at and Microsoft Vault Health Vault failed at." And it's funny we're talking about this. Look, Google just dismantled their health division again. Why? Because tech companies just don't get it. They have a lot of money. They have a lot of power. They've got a lot of smart people. But they they they don't know where, I'll give you an example. It's like a tourist with a lot of money coming into a city. You don't know where the really good local bar is, right? Why is that? You don't know where the really good, you know, slice of pizza is. You're going to go to the regular joints that everyone finds on TripAdvisor and whatever. You know your friends told you, but if you're a local, you know where to get the authentic cocktails and the authentic, you know, drinks and food. Why? Because you've lived and breathed it in the city. So we've lived and breathed it right. And so we know what not to do. It's not about knowing what to do in health care or in genomics or in biotech. It's actually knowing what you shouldn't be doing. Yeah.Harry Glorikian: And knowing I got to tell you, there's some problems where I'm like, OK, I know exactly who to call for that problem, because there aren't, you know, they're not falling off trees in that particular problem. There's a small handful of people that understand that problem well enough that they can come in and sort of surgically help you solve that problem. And you can have all the money in the world and have all the smart people you want. Doesn't mean they're going to be able to solve that particular problem, especially in health care, because it's so arcane.Ardy Arianpour: And it's getting, you know, this is a problem that is growing like cancer, interoperability. Just on this 20 minute conversation with you it has grown by hundreds of millions of dollars. Do you know why? Because data is being siloed.Harry Glorikian: Yeah. And I think, look, I've always I've said this on, you know, whatever show or and I've actually I've written letters to Congress. You know, I think this this needs to be mandated because expecting the large EMR companies to do anything is a waste of time. They're not going to do it on their own if their feet are not put to the fire and it changes. And honestly, I believe that if anything will stop the innovation of health care or slow it down is the EMR systems. You know, if you don't have the data, you can't do the work.Ardy Arianpour: Absolutely. But you know what people don't understand. And not to go off that tangent, but I'll get back to the business model in a second to answer that question because I just recalled in my mind here that I didn't answer that. Look, people don't understand that at least the EMR companies, even though they're like Darth Vader, you know, they needed. They've put some foundation there at least. If that wasn't there, we would be in a much worse situation here, right?Harry Glorikian: Correct, but if Satya Nadella hadn't really changed Microsoft, really redone it right, it wouldn't be the company it is now, and I think they [the EMR companies] are just back in the dark ages.Ardy Arianpour: Of course, I totally agree. I'm surprised, actually. Microsoft, as an example, didn't come up with their own EMR system and launch it to the hospitals to go, compete with the servers and all scripts and Epics of the world. If I was Microsoft, that's what I would do. I would have enough money in power, know exactly what to do. I would take a system like Seqster and I would explode it in a good way and be the good guys and have it completely open source and open network. But that's a whole cocktail conversation if anyone's listening on the on the podcast that wants to talk about that. Give me a call or shoot me an email or find me on LinkedIn.Ardy Arianpour: Let me go back to the business model real quick so people understand. So direct to consumer was what I wanted to do. We built it for the consumer, for the patients. It was the smartest and dumbest thing I ever did. Let's go to why it was the dumbest thing first, because it was really, really hard. It was the smartest because we would not be where we are today. You wouldn't have called me to talk on your podcast and all these other great, you know, amazing people that want to hear about how we're, you know, cracking the code on interoperability now and changing the health care system, changing clinical trials, changing decentralized trials with our system.Ardy Arianpour: Why? Well, it's because our system was built by patients. Right, and so it's a patient centric, real time, real world data platform that layers in engagements for both the providers, the payers, the pharma companies and any other enterprise that white labels our platform. We have both iOS and Android SDK and Web available. It gets fully branded. We're the Intel Inside with the Salesforce.com business model. It's a Software as a Service service that we offer to enterprises. Patients never pay for the service. And we do give VIP codes to chronically ill patients and VIPs, you know, journalists, podcasters and to be honest, anyone who emails me that wants to try it. I've been always giving on that. That costs us time and money, and I'm happy to do it because it's my way of giving back to the community and health care because I know our team and I have built a system that have saved lives. It's been covered by the news multiple times.Harry Glorikian: So, so in essence, a large provider comes, buys the access to the system and then offers it to its patient population to utilize to aggregate all this information, right? How can the platform stay patient centric if the patients aren't directly paying for it?Ardy Arianpour: Ok, very simple. All of these enterprises in health care, whether that's Big Pharma, right, or Big Oayer from Pfizer to Cigna, to United Healthcare group to Humana to even Amazon, right, to other tech companies, they all want to go down a patient centric way. It's just what's happening. You know, I've been talking about this since 2016 because we pioneered patient centric interoperability. That's what we did. That's what Seqster did. That's that's what we set out to do. And we did it. Some, you know, a lot of people say they can do it. Very few actually. Do we fit in that model now, right? And you had the experience yourself. And I think the first time I saw patient centric ads was. 2020. No, sorry. Yeah, 2020, JP Morgan Health Care Conference in January, just three months before the lockdowns and the pandemic started. It was the first time I went to Johnson & Johnson's afterparty in downtown San Francisco. And saw a huge banner saying, you know, blah blah blah, patient centricity. It's the 22nd century, you know, whatever. So they add a bunch of ads that were all patient centric, and I looked to my co-founder, Dana, and I'm like, Look at this, these guys finally caught on. I wonder if they've been, because we've been in discussions with a lot of these folks, long story short, it's not because of Seqster, I think it's just the market was headed that way. We were so far ahead of the market and there was no tailwinds. Now it is all there. And the pandemic afterwards accelerated digital health, as I say, by 7 to 10 years.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's to make it easier for other listeners discover the show by leaving a rating and a review on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing us a huge favor.And one more thing. If you enjoy hearing from the kinds of innovators and entrepreneurs I talk to on the show, I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is out in print and ebook format from Amazon and Barnes & Noble. Just go to either site and search for The Future You by Harry Glorikian. Thanks. And now, back to the show.[musical interlude]Harry Glorikian: So the platform combines EHR, genetic, and fitness data, so. Why did you start with those three?Ardy Arianpour: So we started with those three, and I'll get to that, but we also do pharmacy, social determinants of health, and claims data as well. So we've added three other very large pillars. We can connect to any data source. We've created a universal interoperability platform that's patient centric that brings real time, real world data. And we're just super excited about all the business opportunities and the big pain points that we're solving for enterprise as well as for the patient. Why did we start with genomics, EMR, fitness. Ok. Here's the story. So I named the company Seqster after actually going on a five or six mile run in downtown San Diego, coming back and watching The Italian Job. And in the movie The Italian Job, it's one of my favorite movies, actually. I love that movie. I could just keep watching it over again, the real Napster was in the movie, and I used to be a Napster user where, you know, it was the way of actually pulling all your music and having it kind of in one place. Not really exactly Seqster's model, Seqster's model is is much more legal because it's patient centric. Yes, Napster was kind of stealing the data, right? So long story short, I was trying to think of a company name and I'm like, Oh my God. I don't know what hit me. I'll remember that moment like it was yesterday, Harry. Sequster came up because I had dived into DNA sequencing. We are doing everything that you can on next gen sequencing. And so I was like, Wow! Seqster. S-E-Q-S-T-E-R.Ardy Arianpour: And I went on GoDaddy.com. I bought it for $9.99. And the story started from right then. It was just me and the website. No co-founders, no onee else. I was just thinking, this is a great name. Now, you fast forward to why it's medical data plus genomic data, plus fitness data, to begin with. Well, the genomic data was an easy one because, right, I have 15 years underneath my belt on genomic sequencing technologies and clinical diagnostics and doing a lot of great things for patients in that arena. And I knew that it couldn't just be the genome, right? That's where the medical data came in because we knew and I never knew that we would be able to actually build something that would be able to pull it on together. I knew it was going to be really tough. I didn't think it was going to be this tough. We would have never done it if I knew that it was this tough. It's so great that we did because we solved it. But if you go back and say, "Ardy, would you do it again if you knew it was going to be this tough?" I wouldn't, because it's really, it's not the number two problem, it's the number one problem. And we're just, you know, I'm a peon. I'm a very small dot. I'm not anyone special. I'm just very passionate about solving this problem. That's it. And so is my team, and we got a great team and we've execute on. So great.Ardy Arianpour: And then, you know, it was my idea. I was forcing the wearable and fitness data because I was interested in that. And when the Apple Series One Watch came out, it was very limited, but I saw how it was going to change, you know, just connection of data. And my team being bioinformaticians and from the genomics world were so against bringing it in, I mean, I could show you emails of fights about me saying, get fitness data in here. They were not interested. I forced it on them. And then next thing you knew, clinical trials. One of the biggest things was how do you bring sleeping data and wearable data to x y z data? And that market started taking off. Decentralized trials. You can't even do it if you don't have wearable data. And so everyone started saying, you know, OK, you were right. That was one. I get one big pat on the back. And then we realized we can't be limited to just those three pillars. So what are the next three that we can work on? And that was claims data so we can marry it with the EMR and medical data for payers. And then we ran into pharmacy data. We just signed our first digital pharmacy deal three weeks ago with Paragon Health. And if we didn't have those capabilities, we wouldn't have the business opportunities. And the social determinants of health data being our last integrations comes in very handy for various different use cases.Harry Glorikian: So, three sort of things, right? You know, you combine all this data. What can you learn that wasn't obvious before? How do you translate into better health outcomes for consumers or, say, smarter decision making by consumers, right, so those are two potentially different ways to look at it.Ardy Arianpour: Absolutely. So one word for you: Seqster's longitudinal health record drives health economics, outcomes, research. It drives it.Harry Glorikian: Is that your clients doing that, you doing that, a third party group coming in?Ardy Arianpour: Yeah. We don't do that. We're just the patient engagement and data aggregation operating system that gets implemented for enterprise. And then the enterprise can run the analytics on top of it. They can, you know, take all of the raw data. So we're the only 21 CFR Part 11 compliant platform too. We're fully FDA compliant, Harry. It took us 19 months working with the FDA in order to get our compliance letter in September, October of last year, 2020. So about a year ago. And not only are we HIPAA compliance, not only are we High Trust certified and 256 bit encrypted on all the data that comes in, but having that FDA compliance sets us apart number one. Number two, because we're not an API, we have FHIR fully integrated. We have an API for sharing data, but we're not an API business. We're a SaaS business in health care, in digital health. We can make any company a digital health company. Let's say it's Coca-Cola, and they want to empower their 200,000 employees. They could launch a Coca-Cola Seqster white label in 72 hours to 200,000 employees. That's what we've created. Now, take that and imagine that now within pharma, within precision medicine, within clinical trials, within the payer network, which we're the only platform that's CMS ONC interoperability compliance from the Twenty First Century CURES Act as well.Harry Glorikian: So let me let me see if I... I'm trying to figure out like the angle, right? So I mean, ideally for interoperability, if we talk about the highest level right, you really want to get Epic, Cerner, Kaiser, et cetera, all in a room right? And get them to agree to something. Which is like an act of God.Ardy Arianpour: Some people say, we're doing, you know, it's not my words, but again, a figure of speech, people say, we're doing God's work.Harry Glorikian: But stepping back here for a second, what I see you guys doing is actually giving a platform to the patient and the patient is then connecting the record, not necessarily the systems themselves allowing for interoperability to take place.Ardy Arianpour: So yes, but you're speaking of it because of the direct to consumer experience that you had. The experience we gave you is much different than the experience from the enterprise side. We have a full BI platform built for enterprise as well. Right. And then we have the white label for the enterprise where they launch it to a million patients.Harry Glorikian: That's what, I'm trying to think about that, right? So. Coca-cola says, like, going down your example, Coca-Cola says, "Love to do this. Want to offer it to all of our employees." We make it available to them. But it's the employee that has to push the start button and say, yes, I want my electronic medical record to be integrated into this single platform, right?Ardy Arianpour: But that's that's an example with Coca-Cola. If we're doing something with Big Pharma, they're running a clinical trial for 500,000 COVID patients, as an example. They're getting data collection within one day versus two months, and guess what, we're going to be driving a new possible vaccine. Why? Because of the time it takes for data collection at scale. We empower patients to do that and they get something back. They get to track and monitor all their family health.Harry Glorikian: Right. So so it's sort of, you know, maybe I'm being dense, but sort of the same thing, right? Big Pharma makes it available to the patient. The patient then clicks, Yes, I want to do this and pull in my medical records to make it all everything to be in one place. Yes.Ardy Arianpour: Yes. And I think it's about the fact that we've created a unique data sharing environments. So that's, you know, Harry and Stacey and John and Jennifer and whoever, you know, with whatever use case can share their data and also consent is built with E-consent and digital consent is built within that process. You don't share anything you don't want to share.Harry Glorikian: Right. So let me see if I got this correct. So Seqster is providing a translation and aggregation between systems through a new layer of technology. Not creating true interoperability between systems, right?Ardy Arianpour: Yes. There's a spider web. And. We have untangled the spider beb in the United States of America. We've done all the plumbing and piping to every single health institution, doctor's office clinic, wearable sensor, medical device pharmacy, the list goes on and on, Harry.Harry Glorikian: So let's... Another question. So how does the 21st Century CURES Act of 2016 relate to your business? I think you know you've said something like Seqster has become law, but I'm trying to. I'm trying to understand, what do you mean when you say that?Ardy Arianpour: So when we founded Seqster, we didn't know there was going to be a Twenty First Century CURES Act. We didn't know there was going to be GDPR. We are GDPR compliance before GDPR even came out. Right? Because of our the way that we've structured our business, number one. Number two, how we built the platform by patients for CMS ONC interoperability, you know, final rulings and the Twenty First Century CURES Act, which is, they're synonymous. We worked hand in hand with Don Rucker's team and Seema Verma on the last administration that was doing a lot of the work. Now a wonderful gentleman, Mickey Tripathy has taken the role of ONC, and he understands, you know, the value of Seqster's technology at scale because of his background in interoperability. But what was interesting in the two years that we worked with HHS and CMS was the fact that they used Seqster as the model to build the rules. I was personally part of that, my team was personally part of that, you know, and so we were in private meetings with these folks showing our platform and they were trying to draft certain rules.Ardy Arianpour: We didn't know that they were going to be coming out with rules until they did. And then that's when high level folks in the government told us specifically on calls and also even at Datapalooza when I gave a keynote talk on on Seqster, when Don Rucker did as well right before me. You know, we're sitting in the speaker room and folks are like, "You're going to become law in a month." And this was in February of 2020. March 9th, those rules dropped. I was supposed to give a keynote talk at HL7,  at HIMMS. HIMMS got cancelled in 2020. I just got back from HIMMS 2021 in Vegas just a week and a half ago. It was fantastic. Everyone was masked up. There was only three cases of COVID with 10,000 people there. They did a great job, you know, regulating it. You had to show your vaccine card and all that good stuff. But you know, I would have never thought Seqster becomes law when we were founding the company. And so this is really special now.Harry Glorikian: So what does success look like for Seqster?Ardy Arianpour: It depends how you measure it. So we're in the Olympics. It's a great question. Here's my answer to you. We're in the Olympics just finished, right? So we started out in track and field. We were really good at running the 400 Meters and then somehow we got a use case on the 4x1 and the 4x4. And then we did really well there, too. And then because of our speed, you know, we got some strength and then they wanted us to get into the shot put and the javelin throw and then we started winning there, too. And then somehow, now people are calling us saying, "Are you interested in trying to swim?" We got the 100 meter butterfly. Well, we've never done that. So success for us is based off of use cases. And every use case that we deal with, within clinical trials and pharma, we've define 24 distinct use cases that we're generating business on. Within the payer community now, because of the CMS ONC Twenty First Century Cures Act, there's a major tailwind. Within life insurance for real time underwriting, there's, you know, a plethora of folks that are calling us for our system because of the patient engagement. So this patient centricity for us has been a central pillar, and I've never allowed anyone in our company, whether it's the board or our investors or employees, you know, get sidetracked from that. We've been laser focused on the patients and success at impacting patient lives at scale.Harry Glorikian: So as a venture guide, though, right, like I'm going to, there's only so much money on so much time to tackle, so many different opportunities, right? So it's there is a how do we create a recurring revenue stream and keep plugging along and then generate either enough revenue or raise enough money to do more? And so just trying to think through that for what you guys are trying to do, I get the 4x100 and the swimming. But all of that takes money and resources right to be able to prove out, of course.Ardy Arianpour: And here's another thing we're in a different state. Look, my team and I had a major exit before. We built a billion dollar company out of $3 million. And even though we weren't founders of that company, you know, I was the senior vice president and we we did really well. So, you know, that allowed us to not take salaries that allowed us to take our money and put it into doing something good. And we did that in 2016 to seed it. And then afterwards, I raised, you know, millions of dollars from folks that were interested in, you know, this problem and saw that our team had a track record. And I actually was not interested, Harry, in raising a Series A because of our experience, but we kept on getting calls. And then just six months ago, we announced, you know, our series a funding. Well, we actually announced it in March, I think it was, but we closed our Series A in January of this year and it was led by Takeda Pharma, Anne Wojcicki's 23andMe and United Healthcare Group's Equian folks that created Omniclaim and sold to UnitedHealth Group Omni Health Holdings.Ardy Arianpour: So check this out. Imagine my vision in 2016 of having medical data, genomic data fitness data. Well, if you look at the investors that backed us, it's pretty interesting. What I reflect on is I didn't plan that either. We got amazing genomic investors. I mean, it doesn't get better than getting Anne Wojcicki and 23andMe. Amazing female entrepreneur and, you know, just the just the force. Secondly, Takeda Pharma, a top 10 pharma company. How many digital health startups do you know within Series A that got a top 10 pharma? And then also getting some payer investors from UnitedHealth Group's Omniclaim folks and Equian OmniHealth Holdings. So this is to me, very interesting. But going to focus our focus has been pharma and clinical trials. And so Takeda has been phenomenal for us because of, you know, they they built out the platform and they built it out better for us and they knew exactly what to do with things that we didn't know. And with things that patients didn't know on the enterprise, you know, Takeda did a phenomenal job. And now other pharma companies are utilizing our platform, not just Takeda.Harry Glorikian: Yeah, well, they want their data aggregation. They want as much data on the patient aggregated in one place to make sense of it.Ardy Arianpour: So not necessarily that they actually want to empower patients with a patient centric engagement tool. That's pharma's number one thing right now, the data part, obviously is important, but empowering patient lives at scale is the key, and that's that's our mission. And so, yeah, that's that's a whole 'nother cocktail conversation when I see you soon hopefully in a couple of weeks.Harry Glorikian: Hopefully as life gets, or if it gets back to normal, depending on the variants, you know, we'll hopefully get to meet him in person and have a glass of wine or a cocktail together. So it was great to speak to you. Glad we had this time, and I look forward to, you know, hearing updates on the company and, you know, continually seeing the progress going forward.Ardy Arianpour: Thanks so much, Harry, for having me. Big fan of Moneyball, so thank you to you and your organizers for having me and Seqster on. If anyone wants to get in touch with me personally, you can find me on LinkedIn or you can follow Seqster at @Seqster. And again, thank you so much for. For having a great discussion around, you know, the the insights behind Seqster.Harry Glorikian: Excellent. Thank you.Harry Glorikian: That's it for this week's episode.  You can find past episodes of The Harry Glorikian Show and MoneyBall Medicine at my website, glorikian.com, under the tab Podcasts.Don't forget to go to Apple Podcasts to leave a rating and review for the show. You can find me on Twitter at hglorikian. And we always love it when listeners post about the show there, or on other social media. Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview. 

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: https://www.catalysthealthtech.com/ (CLICK HERE) --- After coming to grips that his professional work was creating data silos, our next guest set out to fix what he sees as healthcare's number one problem- the disconnection of the data ecosystem.   Ardy Arianpour, CEO of Seqster, joins us to discuss how his company has become an industry leader capable of aggregating, standardizing, and visualizing disparate health data into a comprehensive 360-degree view of a patient in real-time.  While together, Ardy also shares why Seqster is poised to help lead the revolution of breaking down data silos.   Join us for this passionate conversation to learn how Ardy and the Seqster team make it quick and easy for anyone to have real-time access to their health data. Let's go!  Episode Highlights: Ardy's beginnings in the healthcare industry that gave him the idea of creating true  longitudinal health records His fateful meeting with Bills Gates and the importance of transparent data sharing The top 3 things that Ardy's most excited about and what sets Seqster apart from other healthcare data companies Ardy's future vision for the industry About our Guest:  Ardy Arianpour is CEO & Co-Founder of Seqster, the leading patient-centric SaaS healthcare technology company that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability.  Ardy is a visionary health tech executive and serial entrepreneur in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He was a Medical, Marketing, and Media's (MM&M) Top 40 Healthcare Transformer and San Diego Business Journal 40 under 40. Links Supporting This Episode: Seqster website: https://www.seqster.com/ (CLICK HERE) Ardy Arianpour LinkedIn page: https://www.linkedin.com/in/ardyarianpour/ (CLICK HERE) Seqster app: http://app.seqster.com (CLICK HERE) Seqster Twitter page: https://twitter.com/Seqster (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest nomination form: https://docs.google.com/forms/d/e/1FAIpQLScqk_H_a79gCRsBLynkGp7JbdtFRWynTvPVV9ntOdEpExjQIQ/viewform (CLICK HERE) Support this podcast

The podcast is back with a new name and a new, expanded focus! Harry will soon be publishing his new book The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer. Like his previous book MoneyBall Medicine, it's all about AI and the other big technologies that are transforming healthcare. But this time Harry takes the consumer's point of view, sharing tips, techniques, and insights we can all use to become smarter, more proactive participants in our own health. The show's first guest under this expanded mission is Dave deBronkart, better known as "E-Patient Dave" for his relentless efforts to persuade medical providers to cede control over health data and make patients into more equal partners in their own care. Dave explains how he got his nickname, why it's so important for patients to be more engaged in the healthcare system, and what kinds of technology changes at hospitals and physician practices can facilitate that engagement. Today we're bringing you the first half of Harry and Dave's wide-ranging conversation, and we'll be back on October 12 with Part 2.Dave deBronkart is the author of the highly rated Let Patients Help: A Patient Engagement Handbook and one of the world's leading advocates for patient engagement. After beating stage IV kidney cancer in 2007, he became a blogger, health policy advisor, and international keynote speaker, and today is the best-known spokesman for the patient engagement movement. He is the co-founder and chair emeritus of the Society for Participatory Medicine, and has been quoted in Time, U.S. News, USA Today, Wired, MIT Technology Review, and the HealthLeaders cover story “Patient of the Future.” His writings have been published in the British Medical Journal, the Patient Experience Journal,  iHealthBeat, and the conference journal of the American Society for Clinical Oncology. Dave's 2011 TEDx talk went viral, and is one the most viewed TED Talks of all time with nearly 700,000 views.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.Full TranscriptHarry Glorikian: Hello. I'm Harry Glorikian. Welcome to The Harry Glorikian Show.You heard me right! The podcast has a new name. And as you're about to learn, we have an exciting new focus. But we're coming to you in the same feed as our old show, MoneyBall Medicine. So if you were already subscribed to the show in your favorite podcast app, you don't have to do anything! Just keep listening as we publish new episodes. If you're not a regular listener, please take a second to hit the Subscribe or Follow button right now. And thank you.Okay. So. Why are we rebranding the show?Well, I've got some exciting news to share. Soon we'll be publishing my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer. It's all about how AI and big data are changing almost everything we know about our healthcare.Now, that might sound a bit like my last book, MoneyBall Medicine. But I wrote that book mainly to inform all the industry insiders who deliver healthcare. Like people who work at pharmaceutical companies, hospitals, health plans, insurance companies, and health-tech startups.With this new book, The Future You, I'm turning the lens around and I'm explaining the impact of the AI revolution on people who consume healthcare. Which, of course, means everyone. That impact is going to be significant, and it's going to change everything from the way you interact with your doctors, to the kind of medicines you take, to the ways you stay fit and healthy.We want you to be prepared for this new world. So we're expanding the focus of the podcast, too. To go along with the new name, we're bringing you interviews with a new lineup of fascinating people who are changing the way patients experience healthcare. And there's nobody better to start out with than today's guest, Dave deBronkart.Dave is best known by the moniker he earned back in the late 2000s: E-Patient Dave. We'll talk about what the E stands for. But all you need to know going in is that ever since 2007, when he survived his own fight with kidney cancer, Dave has been a relentless, tireless advocate for the idea that the U.S. medical system needs to open up so that patients can play a more central role in their own healthcare. He's pushed for changes that would give patients more access to their medical records. And he hasn't been afraid to call out the institutions that are doing a poor job at that. In fact, some folks inside the business of healthcare might even call Dave an irritant or a gadfly. But you know what? Sometimes the world needs people who aren't afraid to shake things up.And what's amazing is that in the years since Dave threw himself into this debate, the world of healthcare policy has started to catch up with him. The Affordable Care Act created big incentives for hospitals and physician practices to switch over to digital recordkeeping. In 2016 the Twenty-First Century Cures Act prohibited providers from blocking access to patients' electronic health information. And now there's a new interface standard called FHIR that promises to do for medical records what HTML and HTTP did for the World Wide Web, and make all our health data more shareable, from our hospital records to our genomics data to the fitness info on our smartphones.But there's a lot of work left to do. And Dave and I had such a deep and detailed conversation about his past work and how patients experience healthcare today that we're going to break up the interview into two parts. Today we'll play the first half of our interview. And in two weeks we'll be back with Part 2. Here we go.Harry Glorikian: Dave, welcome to the show.Dave deBronkart: Thank you so much. This is a fascinating subject, I love your angle on the whole subject of medicine.Harry Glorikian: Thank you. Thank you. So, Dave, I mean, you have been known widely as what's termed as E-patient Dave. And that's like a nickname you've been using in public discussions for, God, at least a decade, as far as I can remember. But a lot of our listeners haven't heard about that jargon word E-patient or know what E stands for. To me, it means somebody who is assertive or provocative when it comes to managing their own health, you know, with added element of being, say, tech savvy or knowing how to use the Internet, you know, mobile, wearable devices and other digital tools to monitor and organize and direct their own care—-all of which happens to describe the type of reader I had in mind when I wrote this new book that I have coming out called The Future You. So how would you describe what E- patient [means]?Dave deBronkart: You know, it's funny because when you see an E-patient or talk with them, they don't stick out as a particularly odd, nerdy, unusual sort of person. But the the term, we can get into its origins back in the 90s someday if you want to, the term has to do with somebody who is involved. What today is in medicine is called patient engagement. And it's funny because to a lot of people in health care, patient engagement means getting the patient to do what they tell us to. Right. Well, tvhere's somebody who's actually an activated, thinking patient, like, I'm engaged in the sense that I want to tell you what's important to me. Right. And I don't just want to do what I'm told. I want to educate myself. That's another version of the E. In general, it means empowered, engaged, equipped, enabled. And these days, as you point out, naturally, anybody who's empowered, engaged and enabled is going to be doing digital things, you know, which weren't possible 20 years ago when the term patient was invented.Harry Glorikian: Yeah, and it's interesting because I was thinking like the E could stand for so many things like, you know, electronic, empowered, engaged, equipped, enabled, right. All of the above. Right. And, you know, I mean, at some point, you know, I do want to talk about access, right, to all levels. But just out of curiosity, right, you've been doing this for a long time, and I'm sure that people have reached out to you. How many E-patients do you think are out there, or as a proportion of all patients at this point?Dave deBronkart: You know, that depends a lot on demographics and stage of life. The, not surprisingly, digital natives are more likely to be actively involved in things just because they're so digital. And these days, by federal policy, we have the ability to look at parts of our medical information online if we want to. As opposed to older people in general are more likely to say just what the doctors do, what they want to. It's funny, because my parents, my dad died a few years ago. My mother's 92. We're very different on this. My dad was "Let them do their work." And my mother is just all over knowing what's going on. And it's a good thing because twice in the last five years, important mistakes were found in her medical record, you know. So what we're at here, this is in addition to the scientific and technological and data oriented changes that the Internet has brought along. We're also in the early stages of what is clearly going to be a massive sociological revolution. And it has strong parallels. I first had this idea years ago in a blog post, but I was a hippie in the 60s and 70s, and I lived through the women's movement as it swept through Boston. And so I've seen lots of parallels. You go back 100 years. I think the you know, we recently hit the 100th anniversary of the 19th Amendment, giving women the right to vote. There were skeptics when the idea was proposed and those skeptics opinions and the things they said and wrote have splendid parallels with many physicians' beliefs about patients.Dave deBronkart: As one example I blogged some years ago, I can send you a link about a wonderful flyer published in 1912 by the National Association Opposed to Women's Suffrage. And it included such spectacular logic as for, I mean, their bullets, their talking points, why we should not give women the vote, the first was "Most women aren't asking for it." Which is precisely parallel to "Most patients aren't acting like Dave, right? So why should we accommodate, why should we adjust? Why should we provide for that? The second thing, and this is another part, is really a nastier part of the social revolution. The second talking point was "Most women eligible to vote are married and all they could do is duplicate or cancel their husband's vote." It's like, what are you thinking? The underlying is we've already got somebody who's voting. Why do we need to bring in somebody else who could only muddy the picture? And clearly all they could do is duplicate or cancel their husband's vote. Just says that the women or the patients, all right, all I could do is get in the way and not improve anything. I bring this up because it's a real mental error for people to say I don't know a lot of E-patients. So it must not be worth thinking about. Harry Glorikian: Yeah, I mean, so, just as a preview so of what we're going to talk about, what's your high-level argument for how we could make it easier for traditional patients to become E-patients?Dave deBronkart: Well, several dimensions on that. The most important thing, though, the most important thing is data and the apps. Harry Glorikian: Yes.Dave deBronkart: When people don't have access to their information, it's much harder for them to ask an intelligent question. It's like, hey, I just noticed this. Why didn't we do something? What's this about? Right. And now the flip side of it and of course, there's something I'm sure we'll be talking about is the so-called final rule that was just published in April of this year or just took effect of this year, that says over the course of the next year, all of our data in medical records systems has to be made available to us through APIs, which means there will be all these apps. And to anybody middle aged who thinks I don't really care that much, all you have to do is think about when it comes down to taking care of your kids or your parents when you want to know what's going on with them. Harry Glorikian: Would you think there would be more E-patients if the health care system gave them easier access to their data? What are some of the big roadblocks right now?Dave deBronkart: Well, one big roadblock is that even though this final federal rule has come out now, the American Medical Group Management Association is pushing back, saying, "Wait, wait, wait, this is a bad idea. We don't need patients getting in the way of what doctors are already doing." There will be foot dragging. There's no question about that. Part of that is craven commercial interests. There are and there have been numerous cases of hospital administrators explicitly saying -- there's one recording from the Connected Health conference a few years ago, Harlan Krumholtz, a cardiologist at Yale, quoted a hospital president who told him, "Why wouldn't I want to make it a little harder for people to take their business elsewhere?"Harry Glorikian: Well, if I remember correctly, I think it was the CEO of Epic who said, “Why would anybody want their data?”Dave deBronkart: Yes. Well, first of all, why I would want my data is none of her damn business. Well, and but that's what Joe Biden -- this was a conversation with Joe Biden. Now, Joe has a, what, the specific thing was, why would you want to see your data? It's 10,000 pages of which you would understand maybe 100. And what he said was, "None of your damn business. And I'll find people that help me understand the parts I want."Harry Glorikian: Yeah. And so but it's so interesting, right? Because I believe right now we're in a we're in a state of a push me, pull you. Right? So if you look at, when you said apps, I think Apple, Microsoft, Google, all these guys would love this data to be accessible because they can then apps can be available to make it more understandable or accessible to a patient population. I mean, I have sleep apps. I have, you know, I just got a CGM, which is under my shirt here, so that I can see how different foods affect me from, you know, and glucose, insulin level. And, you know, I'm wearing my Apple Watch, which tracks me. I mean, this is all interpretable because there are apps that are trying to at least explain what's happening to me physiologically or at least look at my data. And the other day I was talking to, I interviewed the CEO of a company called Seqster, which allows you to download your entire record. And it was interesting because there were some of the panels that I looked at that some of the numbers looked off for a long period of time, so I'm like, I need to talk to my doctor about those particular ones that are off. But they're still somewhat of a, you know, I'm in the business, you've almost learned the business. There's still an educational level that and in our arcane jargon that gets used that sort of, you know, everybody can't very easily cross that dimension.Dave deBronkart: Ah, so what? So what? Ok, this is, that's a beautiful observation because you're right, it's not easy for people to absorb. Not everybody, not off the bat. Look, and I don't claim that I'm a doctor. You know, I still go to doctors. I go to physical therapists and so on and so on. And that is no reason to keep us apart from the data. Some doctors and Judy Faulkner of Epic will say, you know, you'll scare yourself, you're better off not knowing. Well, ladies and gentlemen, welcome to the classic specimen called paternalism. "No, honey, you won't understand." Right now paternal -- this is important because this is a major change enabled by technology and data, right -- the paternal caring is incredibly important when the cared-for party cannot comprehend. And so the art of optimizing and this is where MoneyBall thinking comes in. The art of optimizing is to understand people's evolving capacity and support them in developing that capacity so that the net sum of all the people working on my health care has more competence because I do. Harry Glorikian: Right. And that's where I believe like. You know, hopefully my book The Future You will help people see that they're, and I can see technology apps evolving that are making it easier graphically, making it more digestible so someone can manage themselves more appropriately and optimally. But you mentioned your cancer. And I want to go and at least for the listeners, you know, go a little bit through your biography, your personal history, sort of helping set the stage of why we're having this conversation. So you started your professional work in, I think it was typesetting and then later software development, which is a far cry from E-patient Dave, right? But what what qualities or experiences, do you think, predisposed you to be an E-patient? Is it fair to say that you were already pretty tech savvy or but would you consider yourself unusually so?Dave deBronkart: Well, you know, the unusually so, I mean, I'm not sure there's a valid reason for that question to be relevant. There are in any field, there are pioneers, you know, the first people who do something. I mean, think about the movie Lorenzo's Oil, people back in the 1980s who greatly extended their child's life by being so super engaged and hunting and hunting through libraries and phone calls. That was before there was the Internet. I was online. So here are some examples of how I, and I mentioned that my daughter was gestating in 1983. I took a snapshot of her ultrasound and had it framed and sitting on my office desk at work, and people would say, what's that? Nobody knew that that was going to be a thing now and now commonplace thing. In 1999, I met my second wife online on Match.com. And when I first started mentioning this in speeches, people were like, "Whoa, you found your wife on the Internet?" Well, so here's the thing, 20 years later, it's like no big deal. But that's right. If you want to think about the future, you better be thinking about or at least you have every right to be thinking about what are the emerging possibilities. Harry Glorikian: So, tell us the story about your, you know, renal cancer diagnosis in 2007. I mean, you got better, thank God. And you know, what experience it taught you about the power of patients to become involved in their decision making about the course of treatment?Dave deBronkart: So I want to mention that I'm right in the middle of reading on audio, a book that I'd never heard of by a doctor who nearly died. It's titled In Shock. And I'm going to recommend it for the way she tells the story of being a patient, observing the near fatal process. And as a newly trained doctor. In my case, I went in for a routine physical. I had a shoulder X-ray and the doctor called me the next morning and said, "Your shoulder is going to be fine, but the X-ray showed that there's something in your lung that shouldn't be there." And to make a long story short, what we soon found out was that it was kidney cancer that had already spread. I had five tumors, kidney cancer tumors in both lungs. We soon learned that I had one growing in my skull, a bone metastasis. I had one in my right femur and my thigh bone, which broke in May. I now have a steel rod in my in my thigh. I was really sick. And the best available data, there wasn't much good data, but the best available data said that my median survival. Half the people like me would be dead in 24 weeks. 24 weeks!Harry Glorikian: Yeah.Dave deBronkart: And now a really pivotal moment was that as soon as the biopsy confirmed the disease, that it was kidney cancer, my physician, the famous doctor, Danny Sands, my PCP, because he knew me so well -- and this is why I hate any company that thinks doctors are interchangeable, OK? They they should all fry in hell. They're doing it wrong. They should have their license to do business removed -- because he knew me he said, "Dave, you're an online kind of guy. You might like to join this patient community." Now, think how important this is. This was January 2007, not 2021. Right. Today, many doctors still say stay off the Internet. Dr. Sands showed me where to find the good stuff.Harry Glorikian: Right. Yeah, that's important.Dave deBronkart: Well, right, exactly. So now and this turned out to be part of my surviving. Within two hours of posting my first message in that online community, I heard back. "Thanks for the, welcome to the club that nobody wants to join." Now, that might sound foolish, but I'd never known anybody who had kidney cancer. And here I am thinking I'm likely to die. But now I'm talking to people who got diagnosed 10 years ago and they're not dead. Right? Opening a mental space of hope is a huge factor in a person having the push to move forward. And they said there's no cure for this disease. That was not good news. But the but there's this one thing called high dose Interleukin 2. That usually doesn't work. So this was the patient community telling me usually doesn't work. But if you respond at all, about half the time, the response is complete and permanent. And you've got to find a hospital that does it because it's really difficult. And most hospitals won't even tell you it exists because it's difficult and the odds are bad. And here are four doctors in your area who do it, and here are their phone numbers. Now, ladies and gentlemen, I assert that from the point of view of the consumer, the person who has the need, this is valuable information. Harry, this is such a profound case for patient autonomy. We are all aware that physicians today are very overworked, they're under financial pressure from the evil insurance companies and their employers who get their money from the insurance companies. For a patient to be able to define their own priorities and bring additional information to the table should never be prohibited. At the same time, we have to realize that, you know, the doctors are under time pressure anyway. To make a long story short, they said this this treatment usually doesn't work. They also said when it does work, about four percent of the time, the side effects kill people.Harry Glorikian: So here's a question. Here's a question, though, Dave. So, you know, being in this world for my entire career, it's my first question is, you see something posted in a club, a space. How do you validate that this is real, right, that it's bona fide, that it's not just...I mean, as we've seen because of this whole vaccine, there's stuff online that makes my head want to explode because I know that it's not real just by looking at it. How do you as as a patient validate whether this is real, when it's not coming from a, you know, certified professional?Dave deBronkart: It's a perfect question for the whole concept of The Future You. The future you has more autonomy and more freedom to do things, has more information. You could say that's the good news. The bad news is you've got all this information now and there's no certain source of authority. So here you are, you're just like emancipation of a teenager into the adult life. You have to learn how to figure out who you trust. Yeah, the the good news is you've got some autonomy and some ability to act, some agency, as people say. The bad news is you get to live with the consequences as well. But don't just think "That's it, I'm going to go back and let the doctors make all the decisions, because they're perfect," because they're not, you know, medical errors happen. Diagnostic errors happen. The overall. The good news is that you are in a position to raise the overall level of quality of the conversations.Harry Glorikian: So, you know, talk about your journey after your cancer diagnosis from, say, average patient to E-patient to, now, you're a prominent open data advocate in health care.Dave deBronkart: Yes. So I just want to close the loop on what happened, because although I was diagnosed in January, the kidney came out in March, and my interleukin treatments started in April. And by July, six months after diagnosis, by July, the treatment had ended and I was all better. It's an immunotherapy. When immunotherapy works, it's incredible because follow up scans showed the remaining tumors all through my body shrinking for the next two years. And so I was like, go out and play! And I started blogging. I mean, I had really I had pictured my mother's face at my funeral. It's a, it's a grim thought. But that's how perhaps one of my strengths was that I was willing to look that situation in the eye, which let me then move forward. But in 2008, I just started blogging about health care and statistics and anything I felt like. And in 2009 something that -- I'm actually about to publish a free eBook about that, it's just it's a compilation of the 12 blog posts that led to the world exploding on me late in 2008 -- the financial structure of the U.S. health system meant that even though we're the most expensive system in the world, 50 percent more expensive than the second place country, if we could somehow fix that, because we're the most expensive and we don't have the best outcomes, so some money's being wasted there somewhere. All right. If we could somehow fix that, it would mean an immense amount of revenue for some companies somewhere was going to disappear.Dave deBronkart: Back then, it was $2.4 trillion, was the US health system. Now it's $4 trillion. And I realized if we could cut out the one third that excess, that would be $800 billion that would disappear. And that was, I think, three times as much as if Google went out of business, Apple went out of business and and Microsoft, something like that. So I thought if we want to improve how the system works, I'm happy if there are think tanks that are rethinking everything, but for you and me in this century, we got to get in control of our health. And that had to start with having access to our data. All right. And totally, unbeknownst to me, when the Obama administration came in in early 2009, this big bill was passed, the Recovery Act, that included $40 billion of incentives for hospitals to install medical computers. And one of the rules that came out of that was that we, the patients, had to be able to look at parts of our stuff. And little did I know I tried to use to try to look at my data. I tried to use the thing back then called Google Health. And what my hospital sent to Google was garbage. And I blogged about it, and to my huge surprise, The Boston Globe newspaper called and said they wanted to write about it, and it wasn't the local newspaper, it was the Washington health policy desk. And they put it on Page One. And my life spun out of control.Harry Glorikian: Yeah, no, I remember I remember Google Health and I remember you know, I always try to tell people, medicine was super late to the digitization party. Like if it wasn't for that the Reinvestment and Recovery Act putting that in place, there would still be file folders in everybody's office. So we're still at the baby stage of digitization and then the analytics that go with it. And all I see is the curve moving at a ridiculous rate based on artificial intelligence, machine learning being applied to this, and then the digitized information being able to come into one place. But you said something here that was interesting. You've mentioned this phenomenon of garbage in, garbage out. Right. Can you say more about one of the hospitals that treated you? I think it was Beth Israel. You mentioned Google Health. What went wrong there and what were the lessons you took away from that?Dave deBronkart: Well, there were, so what this revealed to me, much to my amazement, much to my amazement, because I assumed that these genius doctors just had the world's most amazing computers, right, and the computers that I imagined are the computers that we're just now beginning to move toward. Right. RI was wrong. But the other important thing that happened was, you know, the vast majority of our medical records are blocks of text, long paragraphs of text or were back then. Now, it was in a computer then, it wasn't notes on paper, but it was not the kind of thing you could analyze, any more than you could run a computer program to read a book and write a book report on it. And so but I didn't know that. I didn't know what Google Health might do. The next thing that happened was as a result, since Google Health was looking for what's called structured data -- now, a classic example of structured data is your blood pressure. It's fill in a form, the high number, the low number, what's your heart rate? What's your weight, you know? The key value pairs, as some people call them. Very little of my medical history existed in that kind of form. So for some insane reason, what they decided to send Google instead was my insurance billing history.Dave deBronkart: Now, insurance data is profoundly inappropriate as a model of reality for a number of reasons. One of one reason is that insurance form data buckets don't have to be very precise. So at one point I was tested for metastases to the brain to see if I had kidney cancer tumors growing in my brain. The answer came back No. All right. Well, there's only one billing code for it. Metastases to the brain. And that's a legitimate billing code for either one. But it got sent to Google Health as metastases to the brain, which I never had. All right. Another problem is something called up-coding, where insurance billing clerks are trained you can bill for something based on the keywords that the doctors and nurses put in the computer. So at one point during my treatment, I had a CAT scan of my lungs to look for tumors. And the radiologist noted, by the way, his aorta is slightly enlarged. The billing clerk didn't care that they were only checking for kidney cancer tumors. The billing clerk saw aorta, enlarged, aneurysm, and billed the insurance company for an aneurysm, which I never had. Corruption. Corruption. People ask, why are our health care costs so high? It's this system of keyword-driven billing. But then on top of that, I had things that I never had anything like it. There was, when this blew up in the newspaper, the hospital finally released all my insurance billing codes. It turns out they had billed the insurance company for volvulus of the intestine. That's a lethal kink of the intestine that will kill you in a couple of days if it's not treated. Never had anything of the sort. Billing fraud.Harry Glorikian: Interesting.Dave deBronkart: Anyway, because a random patient had just tried to use Google Health and I knew enough about data from my day job to be able to say, "Wait a minute, this makes no sense, why is all this happening?" And I couldn't get a straight answer. You know, it's a common experience. Sometimes you ask a company, "I've got a problem. This isn't right." And sometimes they just blow you off. Well, that's what my hospital did to me. I asked about these specific questions and they just blew me off. So then once it was on the front page of the newspaper, the hospital is like, "We will be working with the E-patient Dave and his doctor." And there's nothing like publicity, huh?[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's to make it easier for other listeners discover the show by leaving a rating and a review on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing us a huge favor.And one more thing. If you like the interviews we do here on the show I know you'll   like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book comes out soon, so keep an eye out for the next announcement.Thanks. And now back to our show.[musical interlude]Harry Glorikian: One of your slogans is "Gimme my damn data," meaning, you know, your patient records. And so can you summarize first, the state of the art prior to this digital transformation? Why was it historically the case that patients didn't have easy access to charts from their doctor's office or their visits? Why has the medical establishment traditionally been reluctant or maybe even unable to share this data?Dave deBronkart: Well, first, I want to explain the origin of that of that term. Because the speech in September of that year that launched the global speaking had that title. What happened was that summer of 2009, my world was spinning out of control as I tried to answer people's questions and get involved in the blogging that was going on and health policy arguments in Washington and so on. And so a real visionary in Toronto, a man named Gunther Eisenbach, who had quite a history in pioneering in this area, invited me to give the opening keynote speech for his annual conference in Toronto that fall. And several times during the summer, he asked me a question I'd never been asked. I came to learn that it was normal, but it was "For our brochure, we need to know what do you want to call the speech? What's the title of the speech?" And I remember very well sitting in my office at work one day saying into the telephone, "I don't know, just call it 'Give me my damn data, because you guys can't be trusted." And much to my amazement, It stuck.Dave deBronkart: I want to be clear. Under the 1996 health information law called hip hop, you are entitled to a copy of every single thing they have about you. All right, and a major reason for that. Back in the beginning was to detect mistakes. So it's interesting because HIPAA arose from health insurance portability. 1996 was when it first became mandatory that you had to be able to take your insurance business elsewhere and therefore your records. And that's the origin of the requirement that anybody who holds your health information as part of your insurance or anything else has to be really careful about not letting it leak out. And therefore and it has to be accurate. Therefore, you have a right to look at it and get any mistakes fixed. But. Foot dragging, foot dragging, foot dragging. I don't want to. As we discussed earlier, there are some doctors who simply wanted to keep you captive. But there are also, the data was also handwritten garbage at times, just scribbles that were never intended to be read by anyone other than the person who wrote the note in the first place. Harry Glorikian: Well, but, you know, I'm not trying to necessarily defend or anything, but but, you know, as you found at Beth Israel Deaconess, and I talk about this in The Future You as well, part of the problem is most of these things that people look at as large electronic health record systems were are still are in my mind designed as accounting and billing systems, not to help the doctors or the patients. And that's still a major problem. I mean, I think until we have, you know, a Satya Nadella taking over Microsoft where he, you know, went down and started rewriting the code for Microsoft Office, you're not going to get to management of patients for the betterment of their health as opposed to let me make sure that I bill for that last Tylenol.Dave deBronkart: Absolutely. Well, and where I think this will end up, and I don't know if it'll be five years or 10 or 20, but where this will end up is, the system as it exists now is not sustainable as a platform for patient-centered care. The early stage that we're seeing now, there is an incredibly important software interface that's been developed in the last five or six years still going on called FHIR, F-H-I-R. Which is part of that final rule, all that. So all of our data increasingly in the next couple of years has to be available through an API. All right. So, yeah, using FHIR. And I've done some early work on collecting my own data from the different doctors in the hospitals I've gone to. And what you get what you get when you bring those all in, having told each of them your history and what medications you're on and so on, is you get the digital equivalent of a fax of all of that from all of them. That's not coordinated, right. The medication list from one hospital might not match even the structure, much less the content of the medication list. And here's where it gets tricky, because anybody who's ever tried to have any mistake fixed at a hospital, like "I discontinued that medicine two years ago," never mind something like, "No, I never had that diagnosis," it's a tedious process, tons of paperwork, and you've got to keep track of that because they so often take a long time to get them fixed. And I having been through something similar in graphic arts when desktop publishing took over decades ago. I really wonder, are we will we ultimately end up with all the hospitals getting their act together? Not bloody likely. All right. Or are we more likely to end up with you and me and all of us out here eventually collecting all the data and the big thing the apps will do is organize it, make sense of it. And here's a juicy thing. It will be able to automatically send off corrections back to the hospital that had the wrong information. And so I really think this will be autonomy enabled by the future, you holding your own like you are the master copy of your medical reality.Harry Glorikian: Yeah, I always you know, I always tell like what I like having as a longitudinal view of myself so that I can sort of see something happening before it happens. Right. I don't want to go in once the car is making noise. I like just I'd like to have the warning light go off early before it goes wrong. But. So you mentioned this, but do you have any are there any favorite examples of patient friendly systems or institutions that are doing data access correctly?Dave deBronkart: I don't want to finger any particular one as doing a great job, because I haven't studied it. Ok. I know there are apps, the one that I personally use, which doesn't yet give me a useful it gives me a pile of fax pages, but it does pull together all the data, it's it's not even an app, it's called My Patient Link. And anybody can get it. It's free. And as long as the hospitals you're using have this FHIR software interface, which they're all required to, by the way, but some still don't. As long as they do this, My Patient Link will go and pull it all together. Now it's still up to you to do anything with it. So we're just at the dawn of the age that I actually envisioned back in 2008 when I decided to do the Google Health thing and the world blew up in my face.Harry Glorikian: Yeah. I mean, I have access to my chart. And, you know, that's useful because I can go look at stuff, but I have to admit, and again, this is presentation and sort of making it easy to digest, but Seqster sort of puts it in a graphical format that's easier for me to sort of absorb. The information is the same. It's just how it gets communicated to me, which is half the problem. But but, you know, playing devil's advocate, how useful is the data in the charts, really? I mean, sometimes we talk as if our data is some kind of treasure trove of accurate, actionable data. But you've helped show that a lot of it could be, I don't want to say useless, but there's errors in it which technically could make it worse than useless. But how do you think about that when you when you think about this?Dave deBronkart: Very good. First note. First of all, you're right. It will...a lot of the actual consumer patient value will, and any time I think about that again, I think a lot of young adults, I think of parents taking care of a sick kid, you know, or middle aged people taking care of elders who have many declining conditions. Right. There's a ton of data that you really don't care about. All right, it's sort of it's like if you use anything like Quicken or Mint, you probably don't scrutinize every detail that's in there and look for obscure patterns or so on. But you want to know what's going on. And here's the thing. Where the details matter is when trouble hits. And what I guarantee we will see some time, I don't know if it'll be five years, 10, or 20, but I guarantee what we will see someday is apps or features within apps that are tuned to a specific problem. If my blood pressure is something I'm.... Six years ago my doctor said, dude, you're prediabetic, your A1C is too high. Well, that all of a sudden brings my focus on a small set of numbers. And it makes it really important for me to not just be tracking the numbers in the computer, but integrate it with my fitness watch and my diet app.Harry Glorikian: Right. Dave deBronkart: Yeah, I lost 30 pounds in a year. And then at the age of 65, I ran a mile for the first time in my life because my behavior changed. My behavior had changed to my benefit, not because of the doctor micromanaging me, but because I was all of a sudden more engaged in getting off my ass and doing something that was important to me.Harry Glorikian: well, Dave, you need to write a diet book, because I could use I could stand to lose like 10 or 20 pounds.Dave deBronkart: Well, no, I'm not writing any diet books. That's a project for another day. Harry Glorikian: That's it for this week's episode. Dave and I had a lot more to talk about, and we'll bring you the second part of the conversation in the next episode, two weeks from now.You can find past episodes of The Harry Glorikian Show and MoneyBall Medicine at my website, glorikian.com. Don't forget to go to Apple Podcasts to leave a rating and review for the show. You can find me on Twitter at hglorikian. And we always love it when listeners post about the show there, or on other social media. Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview. 

On a special edition of PopHealth Week recorded live in the HealthcareNOW Radio studio booth at HIMSS 2021 in Las Vegas, hosts Gregg Masters and Fred Goldstein talk to Ardy Arianpour CEO of Seqster. They discuss their health data management platform which is capable of aggregating, standardizing and harmonizing all of your health data along with allowing you to share on your terms. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

This week another special edition of PopHealth Week recorded live in the HealthcareNOW Radio studio booth at HIMSS 2021 in Las Vegas, our guest is Ardy Arianpour co-founder & CEO @Seqster. Seqster was founded on the vision of a world where individuals own and truly understand all of their health data. Seqster believes that combining multiple data types such as electronic health record (EHR), genetic, and fitness data in one secure place is the key to unlocking optimal health and wealth. In this episode, we discuss Seqster's health data management platform which is capable of aggregating, standardizing. amd harmonizing all of your health data along with allowing you to share on your terms. ==##==  

His family took him out of Iran and arrived in San Diego when he was 6 years old. Today he is a Health Tech pioneer and serial entrepreneur with 18+ years of experience in healthcare applying Technology/ Big Data and Genomics. This week on the podcast we talk with Ardy Arianpour, the CEO and Co- Founder of Seqster. We'll learn more about Ardy's amazing journey to becoming an entrepreneur, and how Seqster is disrupting the Health Tech industry.

Health data is medicine, according to Ardy Arianpour, CEO & Co-Founder of Seqster. Ardy is joined by Real Chemistry's Larry Mickelberg to discuss how we can break down health data silos and what that would mean for the future of healthcare.

Access to all of your health data - MRIs, screenings, and lab results - could be right at your fingertips. COVID-19 put healthcare tech companies into high gear to deliver health data to patients. The end result? Empowered patients, improved clinical trials, and greater control over healthcare decision making. Ardy Arianpour, CEO and co-founder of Seqster, explains how his platform is giving patients ownership and control of their data. Plus, how these technologies are helping clinical trials boost participation and diversity. Plus, a patient advocacy success story! Kate Pecora speaks with Kaitlin Kerr on her advocacy at the state level to fight for marriage equality for SSDI recipients. Hosts: Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public InterestKate Pecora, Field Correspondent, Patients RisingGuests:Ardy Arianpour, CEO and co-founder, SeqsterKaitlin Kerr, Patient AdvocateDiane Talbert, Patient CorrespondentLinks:Drug Prices Are One Focus of Biden's Push to Boost CompetitionSeqster Teams with Rewards Firm Trustr to Incentivize Patient Participation in Clinical Trials FDA chief asks for independent investigation into approval of Biogen's Alzheimer's drug Aduhelm Senator Mensch's Medical Assistance for Workers with Disabilities Signed into Law by GovernorNeed help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

Seqster co-founder and CEO Ardy Arianpour is bringing person-centric interoperability to the masses. With the 21st Century Cures Act, Ardy contends that Seqster essentially is the law.

Listen on Apple, Google, Spotify, and other platforms. Ardy Arianpour, the CEO and co-founder of Seqster, is passionate about the interoperability of healthcare data. Seqster is a platform pioneering patient-centric interoperability to retrieve and seamlessly integrate data from various electronic health records.  Ardy was born in Tehran, Iran but grew up in San Diego. While many Iranian immigrants moved to San Francisco, his family wanted to be as far down the coast as possible while optimizing their entrepreneurial opportunities. He was introduced to the scientific community early, getting his first job at Salk Institute. This opportunity pushed him towards a career in medicine, opting in for a degree in biological sciences at University of California, Irvine. Quickly, he realized that there were opportunities in the science field outside of research or medicine.  He jumped into sales and marketing within the biotech industry, becoming an executive in his late 20s at Cogenics. He later worked with a few startups including Ambry Genetics, Pathway Genetics Corporation, and Basehealth inc. He realized there was opportunity in the genomics field, as a forward-thinking industry, and ended up forming genomic departments at the aforementioned companies.  While building various startups, he realized that data siloing posed problems for both consumers and businesses. He wanted to create a platform that brought together lab, medical, and wearable data, now known as Seqster.  In 2016, Seqster was  formed. In 2017, Ardy began speaking at conferences. In 2018, Bill Gates personally gave Ardy a call, convincing him to take the platform to enterprise with a Business to Business to Consumer (B2B2C) model. However, 2020 was the year Seqster really took off,growing 760% in the span of a year. Ardy says that the pandemic accelerated the digital health space, bringing attention to deficiencies in data infrastructure. This presented a great opportunity for Seqster to grow.  In 2021, the Seqster team is focusing  on pharmaceuticals and life sciences with a data-driven approach. The company will continue to bring innovative technology to enterprises so they can do their jobs more efficiently while also streamlining processes for patients themselves.  Listen in to hear about Ardy’s diverse experiences in the biotech industry and how the San Diego tech community allowed Seqster to thrive.    Ardy’s Favorite Tacos: Roberto’s in Del Mar Connect with Ardy:  LinkedIn Keep up with Seqster: Website LinkedIn Facebook: @seqster Thanks to our partners at Cox Business for their support in enabling us to grow the San Diego ecosystem.

On Health in 2 Point 00, Jess and Matthew talk about TDOC earnings before getting into today's deals. First, Virta Health scores $133 million in a round led by Tiger Global for its keto diabetes reversal program. Seqster raises $12 million in its Series A, and there are some interesting investors in this one. MSK startup Kaia Health raises $75 million, bringing its total to $123 million. Online pharmacy Capsule raises $300 million, bringing its total to $570 million. Finally Accolade acquires virtual primary care platform PlushCare in a $450 million deal.)

Ardy Arianpour is the CEO and co-founder of SEQSTER whose company accidentally fell upon a software that cracked the code of interoperability allowing healthcare providers and patients to access all of their personal health records in one common place. In this interview, Ardy shares the challenges of a siloed healthcare system, struggles of developing a startup, and the importance of leadership decision making. This episode was recorded and published on November 20th, 2019.

Patients deserve easy access to their medical records. With digital healthcare solutions on the rise, new companies are providing patient-centric solutions to gather, own, and share personal health data. Dr. Bob speaks with Seqster CEO and Co-Founder Ardy Arianpour, who is striving to make health data more accessible for patients. And Kate interviews Marie Dagenais-Lewis about creating inclusive workplaces for employees with disabilities. Guest:Ardy ArianpourSeqster, CEO and Co-FounderArdy Arianpour is CEO & Co-Founder of Seqster, an award-winning SaaS healthcare platform that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their U.S.-based healthcare data sources through person-centric interoperability. Ardy is a visionary health tech executive and serial entrepreneur in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 billion. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. He made Medical, Marketing, and Media’s (MMM) list as a Top 40 Healthcare Transformer and was recognized among the San Diego Business Journal’s 40 under 40.Ardy received his bachelor’s degree in biological sciences from UC Irvine and his MBA from Marshall Goldsmith School of Management.Hosts:Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.Kate Pecora, Field Correspondent Links:SeqsterPatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising. 

Ardy Arianpour is the CEO and co-founder of Seqster, an awarding winning SaaS healthcare platform that enables organizations to drive efficient healthcare via comprehensive medical records, individual genomic profiles, and personal device data. In this episode of Health Tech Hustle Podcast with Rodney Hu, Ardy shares his journey from an executive who helped startups grow into large enterprises to a business owner in the science and business field. He also shares the strategies that have seen him fail and rise again to become a successful entrepreneur. Listen in to learn what it takes to build and run a successful SaaS company in the healthcare tech industry.

In episode six we speak with Ardy Arianpour the CEO & Co-Founder at Seqster about how data can make life easier for patients, getting 100K steps per week, and being featured in TIME magazine.

Seqster Founder and CEO Ardy Arianpour explains how the company integrates multiple data sources regarding health care into one system. He discusses How they integrate human genetic information, medical records, and wearable devises, How this becomes a longitudinal record sharable across institutions, and  Why this improves our health care treatment and experience. Ardy Arianpour is a genomics executive and serial entrepreneur in the biotechnology industry and has launched several clinical and consumer-based genetic tests in past companies. He co-founded Seqster in January of 2016. He describes the company as a SaaS healthcare platform used by enterprises in health care fields. It enables organizations to drive efficient healthcare via a comprehensive collection of medical records and electronic health record (EHR) data. It also includes a patient's genomic profile and human genetic information along with any wearable device data and puts this all in one place, allowing individuals to share that data and create a longitudinal health record. He addresses issues of privacy as well, emphasizing the patient-centric mode of this information and the empowering nature of the data alongside protective technology. He provides examples of the usefulness of this platform such as a caregiver's handling of a relative's cancer treatments, having to deal with six different health systems. Rather than lugging binders and CDs of information, all data can be shared across institutions with Seqster. Finally, he shares some recent additions to the system such as a covid-19 compass symptom checker module that is built into the platform for research subjects who may have been exposed. He adds that they are assessing the growth in telehealth, and says that a weakness in telehealth is sharing data, a weakness that Seqster can address.  For best ways to learn more, see seqster.com, follow them on twitter through @Seqster, and find them on LinkedIn.  

On this episode of The Handoff, Dan speaks with Ardy Arianpour, CEO and co-founder of Seqster, a healthcare platform that empowers consumers to aggregate their medical records, genetic data, and fitness data from wearables and other personal health devices into one place.  Ardy grew up in San Diego, the “mecca of genomics,” as the son of a breast cancer survivor, two experiences that shaped his early interest in the field. He was one of the very first people to have his genome mapped and recognized early on that there was a huge opportunity to connect data from disparate sources like wearables, Ancestry.com, 23andme and EHRs. Inspired by Mint.com, he set out to create an individualized health record that would enable people to improve their health by collecting, owning and sharing their data.  He shares with Dan how Seqster combines data interoperability and patient engagement to facilitate meaningful conversations between caregivers and patients and ultimately, drive better health outcomes.  The full transcript for this episode can be found here: www.trustedhealth.com/the-handoff-podcast/ardy-arianpour

On this episode of The Handoff, Dan speaks with Ardy Arianpour, CEO and co-founder of Seqster, a healthcare platform that empowers consumers to aggregate their medical records, genetic data, and fitness data from wearables and other personal health devices into one place.  Ardy grew up in San Diego, the “mecca of genomics,” as the son of a breast cancer survivor, two experiences that shaped his early interest in the field. He was one of the very first people to have his genome mapped and recognized early on that there was a huge opportunity to connect data from disparate sources like wearables, Ancestry.com, 23andme and EHRs. Inspired by Mint.com, he set out to create an individualized health record that would enable people to improve their health by collecting, owning and sharing their data.  He shares with Dan how Seqster combines data interoperability and patient engagement to facilitate meaningful conversations between caregivers and patients and ultimately, drive better health outcomes.  The full transcript for this episode can be found here: www.trustedhealth.com/the-handoff-podcast/ardy-arianpour

A single patient's healthcare data is likely stored in different silos. It can therefore be difficult to assemble a complete picture of health when old records, more recent information, and regularly updated stats from a smartwatch should all be taken into account. Enter Seqster, a Saas solution for compiling healthcare data and making it easily accessible. Ardy Arianpour, cofounder and CEO of Seqster, joins the podcast today to talk about how his product is shaping the future of health.  Show notes Ardy Arianpour is the cofounder and CEO of Seqster. Seqster is a SaaS solution for collecting, owning, and sharing healthcare data.     We want to hear from you Please send us your comments, suggested topics, and listener questions for future All Turtles Podcast episodes.  Email: hello@all-turtles.com Twitter: @allturtlesco

Ardy Arianpour is the CEO and co-founder of SEQSTER whose company accidentally fell upon a software that cracked the code of interoperability allowing healthcare providers and patients to access all of their personal health records in one common place. In this interview, Ardy shares the challenges of a siloed healthcare system, struggles of developing a startup, and the importance of leadership decision making.

In this mini episode of the podcast recorded at HLTH in Las Vegas, Marc Iskowitz sits down with Seqster's Ardy Arianpour, founder and CEO, about his session, the health-data interoperability company's just-announced deal with La Jolla Institute for Immunology, its future plans, and what he's gleaned over the first two days of the conference.

Founder of Seqster, newly named winner of the National Readmission Prevention Collaborative Innovation Contest, Ardy Arianpour joins the show on Dr. Luke’s Waiting Room: The Healthcare Authority Podcast. 

What will patients do if they have their aggregated medical record? Perhaps move faster enough to save a life. Ardy Arianpour of Seqster talks about his passion to empower patients with their medical data. Hope you enjoy.

Robin chats with Ardy Arianpour, CEO & Co-Founder of Seqster, a data-driven healthcare SaaS platform that seamlessly integrates into any payer, provider, or clinical research enterprise. Seqster is at the forefront of the movement to integrate baseline genetic data, including DNA, with patient electronic medical records.  Seqster’s business model is business to business, through SaaS, where businesses license the platform and Seqster delivers the integrated information to their members. Seqster has created a consumer management data exchange in which patients can monitor and correct their own or a loved one’s medical information, through the aggregation of data from different health systems, wearable data, and ancestral data in incredibly short timeframes and in an overall patient centric framework. This episode is sponsored by J & B Medical, www.jandbmedical.com and Life365, Inc., www.life365inc.com

Has Seqster discovered the holy grail of interoperability? The San Diego-based startup has developed a tool that pulls health data from multiple EHRs, connecting the fragmented pipes of healthcare. In this episode, Marc talks with Ardy Arianpour, CEO and cofounder of Seqster, about how his team happened upon a solution to a problem that has stumped the likes of Microsoft, Google and Apple.

“Our priority is creating a person-centric interoperability platform”

In this podcast, Ardy Arianpour, CEO of Seqster (pronounced Seekster), shares the origin story for creating what he calls, “the Mint.com of health care. Seqster is creating a clear, direct, one-password-only channel between patients and ALL their healthcare data – EHR, genetic and fitness, etc. The start-up is marking its offering to payers and providers and already has secured access to data from 3,000 hospitals and 45,000 physician offices as well as DNA Labs and data-collecting Medtechs like ResMed and DexCom. Hear Arianpour vision for the future of healthcare data.

Today's guest: Ardy Arianpour | Co-Founder and CEO of Seqster Greg and Ardy talk about the possibilities created by Seqster - the "Mint.com of health data."Ardy Arianpour is CEO & Co-Founder of Seqster, a data-driven healthcare SaaS platform that seamlessly integrates into any payer, provider, or clinical research enterprise. Seqster provides person-centric interoperability to retrieve and harmonize electronic health records (EHR), genetic, and continuous monitoring data from distinct sources. Ardy is a visionary health tech executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and SVP of Ambry Genetics that sold to Konica for $1B in 2017. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management.   Important links: Seqster Web Site: https://seqster.com/Ardy's LinkedIn: https://www.linkedin.com/in/ardyarianpour/Eric Topol's Post about Seqster: https://twitter.com/EricTopol/status/1031970997707010048Article: Seqster’s Perfect Timing, Powerful Platform Might Change Health: http://www.bio-itworld.com/2018/09/18/seqsters-perfect-timing-powerful-platform-might-change-health.aspx

In this episode we’re talking about data. We dive into two key aspects of data access. One aspect is about what happens to our health data when we die. Millions of people die each year and the information stored in their lost to their families and future generations. The other aspect we cover in this episode relates to the popular topic of interoperability. For decades, this has been the subject of countless conferences and meetings and even congressional hearings. We reluctantly accept the fact that our medical records are distributed across various systems and providers, but that poses a real problem both to people who are accessing care, and the people and organizations providing it. It’s not just that it’s inconvenient, it can actually undermine accurate diagnosis and treatment, and negatively impact outcomes.  [...] Get the full show notes here. --- This episode is made possible thanks to our sponsors. --- Learn more about your ad choices. Visit megaphone.fm/adchoices

Read the transcript In this fourth episode, Ardy Arianpour, CEO and Co-Founder of Seqster, shares why the future of your health data is a centralized view, controlled by you, pulled from wearables, genetic tests, logged nutritional intake as well as your medical records even if spread across medical institutions. He relates the unique ability and need to share our lifetime of health data transgenerationally. Topics we discussed in this episode Apple's acquisition of Gliimpse in 2016 Google's failed attempt of personal health data storage Microsoft HealthVault Apple Medical Records Why Seqster is different from other services offering to collate your medical records The consumer value of longitudinally matched data sets, particularly multi-generational The hijacking of Electronic Medical Records for greater profit rather than patient care The ability to provide a single unified view of our health data, spanning wearable devices, to lab tests such as genetics, to our electronic medical records even if spread over multiple institutions The reluctance of orthodox healthcare to liberate our health data The creation of a new legal framework to share our lifetime of health data with our family and/or society, posthumous Show links Seqster Website Chain of Custody Wikipedia Entry PatientBank Shutdown Notification Blog Post National Institutes of Health (NIH) — All of Us Research Program Web Page Gliimpse CrunchBase Entry Picnic Health Website Heads Up Health Website Fast Healthcare Interoperability Resources (FHIR) Wikipedia Entry Affective Computing Wikipedia Entry Google Health Wikipedia Entry Stanford Medicine September 2018 White Paper: The Future of Electronic Health Records PDF An American Sickness: How Healthcare Became Big Business and How You Can Take It Back by Elisabeth Rosenthal Book Hyper Wellbeing 2016 Conference Video - Walter De Brouwer: From IA to AI in Healthcare Microsoft HealthVault Web Page HumanAPI Website Apple Health Records Web Page

As long as we’ve been doing clinical genetics, the goal has been to marry up the genetic data with phenotypic data in the electronic medical records. This has been achieved with some success and with a few of the best genetic markers at some of the leading healthcare providers: Geisinger, Rady Children's, Brigham and Women’s—to name a few. But it hasn’t happened at scale, at least not in this country. Some of the national health services around the world are making the dream more of a reality, for example in Iceland and the U.K.

Self-described Genomics Ninja Jedi, Ardy Arianpour, is now CEO & Co-Founder at Seqster, a consumer driven healthcare technology platform. They are using AI to allow people to aggregate their electronic health, genomics and fitness records so they and family members can view it and use the information as needed. In this interview, Arianpour discusses why this advancement is so important to the healthcare industry and how it is being used. We've all been there. You are desperately scrambling to track down and consolidate your very own medical records. You're spending countless hours online and on the phone, only to end up at a dead-end or with any luck, a mess of information. Seqster's ground-breaking platform aims to solve this problem. The platform allows consumers to access and gather their medical and fitness data all in one place, creating a multi-generational health record. In addition to your family having access to your health records and progress during your lifetime, your doctor can also easily access the most accurate and current information – ensuring the most appropriate and timely care is being administered. Much like having all of your financial information in one place, Seqster believes having better and more health data in one spot, ultimately leads to a better overall healthcare experience. Join us for a fascinating discussion, as Arianpour details how Seqster is changing the world of healthcare as we know it. Bio: Ardy Arianpour is CEO & Co-Founder of Seqster, the first consumer driven healthcare technology platform that utilizes A.I. to enable individuals to aggregate their EHR, genomics and fitness data in one place and share with their family creating a multi-generational health record. Ardy is a visionary genomics executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and SVP of Ambry Genetics that sold to Konica for $1B in 2017. He is one of the main architects in launching the first commercial clinical exome sequencing test in 2011, establishing the value of next-gen sequencing in the clinic. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management.